|6th November 2020||Capital Management, Llc Aquilo||5,000||Open or private sale||$13.77||$68,873.50|
|5th November 2020||Capital Management, Llc Aquilo||96,600||Open or private sale||$13.98||$1,350,332.76|
|4th November 2020||Capital Management, Llc Aquilo||72,500||Open or private sale||$14.26||$1,033,741.25|
|23rd October 2020||Ankit Mahadevia||20||Open or private sale||$14.25||$285.00|
|23rd October 2020||Ankit Mahadevia||20||Exercise of derivative||$5.90||$118.00|
|14th October 2020||Ankit Mahadevia||105||Open or private sale||$14.25||$1,496.25|
|14th October 2020||Ankit Mahadevia||105||Exercise of derivative||$5.90||$619.50|
|13th October 2020||Ankit Mahadevia||14,367||Exercise of derivative||$5.90||$84,765.30|
|13th October 2020||Ankit Mahadevia||14,367||Open or private sale||$14.28||$205,212.48|
|8th September 2020||Ankit Mahadevia||774||Exercise of derivative||$5.90||$4,566.60|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013.